Janux Therapeutics, Inc.
JANXNASDAQHealthcare● Active
$13.51
+$0.15(+1.12%)
Market Cap$823898623
P/E Ratio—
52W High$35.34
52W Low$12.12
Janux Therapeutics, Inc. (JANX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
JANX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.39
Est. -$0.52 · +25.0%
Revenue
$0.00B
Est. $0.00B · -14.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 3-Quarter EPS Beat Streak
JANX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.31 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.52 | -$0.39 | +25.0% | $0.00B | $0.00B | -14.3% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.65 | -$0.51 | +21.5% | $0.01B | $0.00B | +9356.0% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.60 | -$0.39 | +35.0% | $0.01B | — | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.48 | -$0.55 | -14.6% | — | $0.00B | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.43 | -$0.38 | +11.6% | — | $0.00B | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.49 | -$0.36 | +26.5% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.37 | -$0.51 | -37.8% | $0.00B | $0.00B | -70.6% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.31
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.39
EPS Est.
-$0.52
EPS Surpr.
+25.0%
Revenue
$0.00B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
-$0.51
EPS Est.
-$0.65
EPS Surpr.
+21.5%
Revenue
$0.01B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.39
EPS Est.
-$0.60
EPS Surpr.
+35.0%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.48
EPS Surpr.
-14.6%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.38
EPS Est.
-$0.43
EPS Surpr.
+11.6%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.49
EPS Surpr.
+26.5%
Revenue
—
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.51
EPS Est.
-$0.37
EPS Surpr.
-37.8%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.87 | $-0.55 | $-0.23 | 5 |
| Q3 FY2028 | $-0.86 | $-0.55 | $-0.23 | 5 |
| Q2 FY2028 | $-0.97 | $-0.61 | $-0.26 | 5 |
| Q1 FY2028 | $-1.05 | $-0.67 | $-0.28 | 5 |
| Q4 FY2027 | $-1.24 | $-0.79 | $-0.33 | 4 |
| Q3 FY2027 | $-1.09 | $-0.69 | $-0.29 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 4 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +25.0% | $14.62 | $14.54 | -0.55% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +21.5% | $13.70 | $13.80 | +0.73% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +35.0% | $27.54 | $28.66 | +4.07% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -14.6% | $24.18 | $22.58 | -6.62% |
| ▲ Q2 FY2025 | May 8, 2025 | +11.6% | $25.70 | $26.37 | +2.61% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +26.5% | $32.60 | $32.01 | -1.81% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -37.8% | $55.28 | $54.89 | -0.71% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +65.6% | $36.90 | $35.29 | -4.36% |
Q2 FY2026-0.55%
Report Date
May 7, 2026
EPS Beat/Miss
+25.0%
Price Before
$14.62
Price After
$14.54
Q1 FY2026+0.73%
Report Date
Feb 26, 2026
EPS Beat/Miss
+21.5%
Price Before
$13.70
Price After
$13.80
Q4 FY2025+4.07%
Report Date
Nov 6, 2025
EPS Beat/Miss
+35.0%
Price Before
$27.54
Price After
$28.66
Q3 FY2025-6.62%
Report Date
Aug 7, 2025
EPS Beat/Miss
-14.6%
Price Before
$24.18
Price After
$22.58
Q2 FY2025+2.61%
Report Date
May 8, 2025
EPS Beat/Miss
+11.6%
Price Before
$25.70
Price After
$26.37
Q1 FY2025-1.81%
Report Date
Feb 27, 2025
EPS Beat/Miss
+26.5%
Price Before
$32.60
Price After
$32.01
Q4 FY2024-0.71%
Report Date
Nov 6, 2024
EPS Beat/Miss
-37.8%
Price Before
$55.28
Price After
$54.89
Q3 FY2024-4.36%
Report Date
Aug 7, 2024
EPS Beat/Miss
+65.6%
Price Before
$36.90
Price After
$35.29
Avg Beat Reaction+0.11%
Avg Miss Reaction-3.67%
Beat Rate6 / 8 quarters
Largest Move-6.62% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: JANX ends December
Janux Therapeutics, Inc. (JANX) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.39 — beating the analyst consensus of $-0.52 by +25.0%. JANX has beaten EPS estimates for 3 consecutive quarters. The next JANX earnings date is expected around September 1, 2026.
Each quarter, investors track JANX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. JANX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
JANX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
JANX earnings · 5 questionsJanux Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. JANX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; JANX historically reports after market close (AMC).
JANX earnings datewhen is JANX earningsJANX next earnings datewhen does JANX report earningsJANX earnings calendar
▸ Source: FMP · Janux Therapeutics, Inc. SEC filings · US GAAP · Janux Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026